TY - JOUR
T1 - Circulating prolactin and in situ breast cancer risk in the European EPIC cohort
T2 - A case-control study
AU - Tikk, Kaja
AU - Sookthai, Disorn
AU - Fortner, Renée T.
AU - Johnson, Theron
AU - Rinaldi, Sabina
AU - Romieu, Isabelle
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Overvad, Kim
AU - Clavel-Chapelon, Françoise
AU - Baglietto, Laura
AU - Boeing, Heiner
AU - Trichopoulou, Antonia
AU - Lagiou, Pagona
AU - Trichopoulos, Dimitrios
AU - Masala, Giovanna
AU - Krogh, Vittorio
AU - Tumino, Rosario
AU - Ricceri, Fulvio
AU - Mattiello, Amalia
AU - Agudo, Antonio
AU - Menéndez, Virginia
AU - Sánchez, María José
AU - Amiano, Pilar
AU - Chirlaque, Maria Dolores
AU - Barricarte, Aurelio
AU - Bueno-de-Mesquita, Hbas
AU - Monninkhof, Evelyn M.
AU - Onland-Moret, N. Charlotte
AU - Andresson, Anne
AU - Sund, Malin
AU - Weiderpass, Elisabete
AU - Khaw, Kay Tee
AU - Key, Timothy J.
AU - Travis, Ruth C.
AU - Merritt, Melissa A.
AU - Riboli, Elio
AU - Dossus, Laure
AU - Kaaks, Rudolf
PY - 2015/3/31
Y1 - 2015/3/31
N2 - Introduction: The relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention. Methods: We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects. Results: We found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2=1.35 (95% CI 1.04-1.76), Ptrend=0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet=0.98) or baseline HT use (Phet=0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend=0.06 vs Ptrend=0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors <4 years compared to ≥4 years after blood donation (Ptrend=0.01 vs Ptrend=0.63; Phet=0.04) and among nulliparous women compared to parous women (Ptrend=0.03 vs Ptrend=0.15; Phet=0.07). Conclusions: Our data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.
AB - Introduction: The relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention. Methods: We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, including 307 in situ breast cancer cases and their matched control subjects. Results: We found a significant positive association between higher circulating prolactin levels and risk of in situ breast cancer among all women [pre-and postmenopausal combined, ORlog2=1.35 (95% CI 1.04-1.76), Ptrend=0.03]. No statistically significant heterogeneity was found between prolactin levels and in situ cancer risk by menopausal status (Phet=0.98) or baseline HT use (Phet=0.20), although the observed association was more pronounced among postmenopausal women using HT compared to non-users (Ptrend=0.06 vs Ptrend=0.35). In subgroup analyses, the observed positive association was strongest in women diagnosed with in situ breast tumors <4 years compared to ≥4 years after blood donation (Ptrend=0.01 vs Ptrend=0.63; Phet=0.04) and among nulliparous women compared to parous women (Ptrend=0.03 vs Ptrend=0.15; Phet=0.07). Conclusions: Our data extends prior research linking prolactin and invasive breast cancer to the outcome of in situ breast tumours and shows that higher circulating prolactin is associated with increased risk of in situ breast cancer.
UR - https://www.scopus.com/pages/publications/84928579941
U2 - 10.1186/s13058-015-0563-6
DO - 10.1186/s13058-015-0563-6
M3 - Article
C2 - 25887963
AN - SCOPUS:84928579941
SN - 1465-5411
VL - 17
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 1
M1 - 49
ER -